The immunohistochemical (IHC) profile of the tumor indicated estrogen receptor (ER) expression at 95%, progesterone receptor (PR) expression at 98%, a Ki67 index of 30%, and a HER2/neu score of +3. This evidence concerns the gene ERBB2 and neoplasm.